Compare MTDR & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MTDR | COGT |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 5.9B |
| IPO Year | 2011 | 2018 |
| Metric | MTDR | COGT |
|---|---|---|
| Price | $60.36 | $32.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 15 |
| Target Price | ★ $63.07 | $36.21 |
| AVG Volume (30 Days) | ★ 1.5M | 1.4M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.38% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,696,277,000.00 | $7,871,000.00 |
| Revenue This Year | $7.15 | N/A |
| Revenue Next Year | $7.63 | $1,733.58 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.46 | N/A |
| 52 Week Low | $37.14 | $4.55 |
| 52 Week High | $66.84 | $43.73 |
| Indicator | MTDR | COGT |
|---|---|---|
| Relative Strength Index (RSI) | 53.75 | 30.56 |
| Support Level | $53.44 | $14.00 |
| Resistance Level | $63.88 | $37.69 |
| Average True Range (ATR) | 1.84 | 1.36 |
| MACD | -0.26 | -0.33 |
| Stochastic Oscillator | 63.93 | 0.59 |
Matador Resources Co is an independent energy company engaged in the exploration, development, production, and acquisition of oil and natural gas resources. The majority of the company's assets are located in the United States, with an emphasis on oil and natural gas shale and other unconventional plays. Along with maintaining a portfolio of oil and natural gas properties, Matador works to identify and develop midstream opportunities that support and enhance its exploration and development business. The Company has two reportable business segments: exploration and production and midstream. The company generates majority of its revenue from the exploration and production segment.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.